IDH1 and glioma: Traditionally, glioma classification as suggested by the WHO was mainly based on histopathology and first molecular markers including IDH mutations, ATRX loss and 1p/19q codeletion have been integrated into routine glioma subtyping since the updated WHO criteria published in 2016 (Louis et al., 2007a,b, 2016).